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Purification of HIF-polyarginine Peptide (HIF1) 
HIF1 (H2N-(CH2)5CO-ALAPYIP-(D-Arg)8NH2) was purified by RP-HPLC (Rainin 
Dynamax System) comprising two solvent delivery pumps (Model SD200) and variable 
wavelength detector (model UV-1) set at 214nm. The column used was an YMC-Pack 
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ODS-AM, 250 x 20 mm, 5µm particle size and 120Å pore size (Waters, Milford, MA) 
coupled to a guard column ODSA (10 x 10mm) with the same stationary phase 
specifications. The separation was carried out with a linear gradient of solvent A 
(H2O/CH3CN 98:2 + 0.06% of TFA) into solvent B (CH3CN/H2O 80:20 + 0.05% of 
TFA): 15% of B to 35% of B over 85min, 35% B to 98% B over 15 min, run at 
5.0ml/min. HIF1 was eluted at 69 min.  MALDI-TOF analysis of peptide samples were 
performed in a Voyager-DE- PRO 6268 (Applied Biosystems) using a-cyano-4-
hydroxycinnamic acid matrices.  Analytical HPLC traces of purified samples was carried 
out in a Waters Separation Module 2795 coupled to a Waters 2795 Photodiode Array 
Detector (set at 214nm) and to a Micromass ZQ 4000 Electrospray Mass detector (cone 
voltage = +120V). A linear gradient of Solvent A (composition as described for 
preparative separations) into Solvent B, 2% B to 37.5% B over 63min, was run at 
0.2ml/min.  The analytical column used was an XTerra MS C18 (4.6mm x 50mm, 2.5µm 
particle size, 80Å pore size). 
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Figure 1: MALDI-TOF spectrum of purified HIF 1 sample used on the synthesis of (3). 
Analytical conditions are described above. 
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Figure 2: HPLC chromatogram (UV trace) of purified HIF 1 used in the synthesis of 
Protac-2.  Analytical conditions are described above. 
 
Preparation of PROTAC-4 (3). 
 AP21998 (1) was synthesized as previously described21,22, as a 1:1 mixture of 
diastereomers at C9.  To a solution of 15 mg (0.021mmol) of 1 in 1mL DMF was added 
6.8mg (0.023mmol) EDCI, 6.4mg (0.053mmol) DMAP,  and 4.6mg (0.021mmol) H2N-
(CH2)5CO2Bn.  The reaction was stirred for 24h, and filtered through Celite filter agent.  
Solvent was removed under vacuum, and the crude product (16mg) was redissolved in 
2mL ethanol.  To this solution was added 20mg 10% Pd/C, the reaction was placed under 
an atmosphere of hydrogen (balloon) and stirred for 1h.  The reaction was filtered 
through Celite, after which the solvent was removed in vacuo to yield 12mg of crude 
product (2).  This material was carried on without further purification. 
 Crude 2 (12mg, 0.014mmol) was added to a 5mL round bottomed flask along 
with 3mg (0.0014mmol) HIF1 H2N-(CH2)5CO-ALAPYIP-(D-Arg)8NH2 (W.M. Keck 
Foundation Biotechnology Resource Laboratory), 1mg  PyBrOP, 1µL 
diisopropylethylamine, and 0.6mL dry DMF.  The reaction mixture was stirred for 18 
hours, after which solvent was evaporated under a high vacuum. 
  Crude mixture of 3 was purified by RP-HPLC (for HPLC system and column 
specifications see the purification procedure for HIF 1). A linear gradient of Solvent A 
into B (same solvents composition as described for HIF 1) consisting of 2% B to 37% B 
over 63 min, 37% B to 75% B over 37 min, 75% B to 98% B over 10 min, 98% B for 20 
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min, was run at 5.0 mL/min. 3 was eluted at 95 min.  MALDI-TOF analyses of purified 
samples were performed in a Voyager-DE- PRO 6268 (Applied Biosystems) using a-
cyano-4-hydroxycinnamic acid matrices.  Purified samples were analyzed by LC-MS (see 
HIF 1 for equipment, column specifications and solvent composition and analytical 
parameters) using a linear gradient of B into A: 2% B to 100% B over 40 min, 100% B 
for 20 min, run at 0.2 mL/min. 
Compound 1.  1H NMR (CDCl3, 400 MHz) (Mixture of rotamers and diastereomers) 
1(S) 7.19 (t, J=7.9Hz, 1H), 6.67-6.96 (m, 6H) 6.24 (s, 2H), 5.48-5.50 (m, 2H) 4.60-4.74 
(m, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.78 (s, 3H), 3.61-3.93 (m, 2H), 3.55 (s, 6H), 2.85-
2.93 (m, 1H), 2.56-2.68 (m, 2H), 1.98-2.36 (m, 4H), 1.63-1.77 (m, 4H), 1.26-1.46 (m, 
2H), 0.90 (t, J-7.3Hz, 3H).  1(R) 7.25 (t, J=7.8 Hz), 6.70-6.90 (m, 6H), 6.45 (s, 2H), 5.66-
5.70 (m, 1H), 5.53 (d, J=4.5Hz, 1H), 4.59-4.72 (m, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.84 
(s, 3H), 3.83 (s, 6H), 3.47-3.79 (m, 2H), 3.23-3.32 (m, 1H), 2.52-2.71 (m, 2H), 2.00-2.31 
(m, 4H), 1.52-1.75 (m, 4H), 1.28-1.46 (m 2H), 0.83 (t, J=7.3Hz, 3H); LRMS (ES) (M + 
H)+ calc 694.32, meas. 694.7. 
 
Structural assignment of 1 based on original synthesis:  Yang, W., et. al. J. Med. Chem.  
2000, 43, 1135-1142. 
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Figure 3: MALDI-TOF spectrum of purified 3. Analytical conditions described above. 
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Figure 4: HPLC chromatogram (UV trace) of purified 3.  Analytical conditions described 
above. 
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Preparation of PROTAC-5 (5). 
Compound 4 was synthesized as previously described33.  To a solution of 1.2mg 
(0.003mmol) 4 in 1mL DMF was added 2mg H2N-(CH2)5CO-ALAPYIP-(D-Arg)8NH2, 
0.3mg (0.014mmol) EDCI, and 0.2mg (0.015mmol) DMAP.  The reaction mixture was 
stirred for 24h, after which solvent was evaporated under high vacuum.  The product was 
purified by HPLC to yield 1.3mg 5. 
 The purification procedure was carried out using same equipment, column and 
Solvents A and B composition as described for HIF 1 and PROTAC-4 (3). A linear 
gradient was done by adding Solvent B into Solvent A: 40%B to 70%B over 100min, 
70%B to 98%B over 20min, run at 5.0mL/min.  Compound 5 eluted at 30min. Purified 
samples were analyzed by MALDI-TOF using the same parameters as described earlier.  
Purified samples of 5 were analyzed by LC-MS using a linear gradient consisting of 2%B 
to 40%B over 40min. Analytical conditions, equipment and parameters were the same 
used for HIF 1 and 3. 
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Figure 5: MALDI-TOF spectrum of purified 5. Analytical conditions are described 
above. 
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Figure 6: HPLC chromatogram (UV trace) of purified 5.  Analytical conditions are 
described above. 
